@sciencedirect study: Mortality risk greater among Veterans not receiving buprenorphine pharmacotherapy (dupe) than those who did. Providers should consider whether bupe, intermittent or continuous, may provide health benefits for their patients & p…
RT @AddictionPolicy: A recent study from @sciencedirect assessed the mortality outcomes with buprenorphine pharmacotherapy among Veterans u…
A recent study from @sciencedirect assessed the mortality outcomes with buprenorphine pharmacotherapy among Veterans up to 5 years from treatment initiation. https://t.co/e2mwKrSvlB
RT @emupdates: Among 29,054 veterans with opioid use disorder, death by suicide or overdose was FOUR TIMES less likely on days the patient…